Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

S 38093

Next Previous
Drug Profile

S 38093

Alternative Names: S38093

Latest Information Update: 23 Jul 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Servier
  • Class Antidementias
  • Mechanism of Action Histamine H3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease

Most Recent Events

  • 23 Jul 2015 Phase-II development is ongoing in the United Kingdom
  • 01 Jan 2015 Servier completes a phase II trial in Alzheimer's disease (Combination therapy, In adults, In the elderly) in Austria, Finland, Italy, Germany, Poland, Portugal, Spain, Sweden, Slovakia and United Kingdom (EudraCT2011-005862-40)
  • 01 Apr 2014 Servier completes a phase II trial in Alzheimer's disease in Australia, Brazil, Bulgaria, Chile, Czech Republic, France, Germany, Hungary , Mexico, Portugal, Romania, Russia and South Africa (EudraCT2010-024626-37)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top